The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | Considering the use of gene therapy in severe inherited thrombophilia
Beverley Hunt, OBE, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, comments on whether the use of gene therapy should be considered in patients with severe inherited thrombophilia. The advent of gene therapy has led to patients with hemophilia being relieved of the disease; however, Prof. Hunt emphasizes that the longevity of these outcomes is not yet known and that data must mature before gene therapy can be considered and trialed in high-risk thrombophilia. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
